ArticleAsian Pacific journal of cancer prevention : APJCP2020
Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Diagnostic and Therapeutic Value of the Exercise-Induced Myokine Irisin in Cancer Biology: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- Irisin's Dual Role in Malignant Tumors and Its Potential as a Biomarker and Therapeutic Target.Drug design, development and therapy · 2025Review
- Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer.Reports of biochemistry & molecular biology · 2024Article
- The Modulation of Adipokines, Adipomyokines, and Sleep Disorders on Carcinogenesis.Journal of clinical medicine · 2023Review
- The Relationship between Circulating Irisin and Oxidative Stress in Gastric and Colorectal Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers.Journal of clinical medicine · 2022Review
- Low FNDC5/Irisin expression is associated with aggressive phenotypes in gastric cancer.Frontiers in pharmacology · 2022Article
- Irisin and Carcinoembryonic Antigen (CEA) as Potential Diagnostic Biomarkers in Gastric and Colorectal Cancers.Reports of biochemistry & molecular biology · 2021Article
- Progress and Challenges in the Biology of FNDC5 and Irisin.Endocrine reviews · 2021Review
- The Role of Irisin in Cancer Disease.Cells · 2021Review
- Review
- Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review.International journal of molecular sciences · 2021Review
- The role of Irisin in multiorgan protection.Molecular biology reports · 2021Review
- Serum Levels of Irisin and Omentin-1 in Breast Neoplasms and Their Association with Tumor Histology.International journal of endocrinology · 2021Article
- Review of Research on the Role of Irisin in Tumors.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThere is much evidence of an association between cancer and irisin that is an adipokine. This study researched on the relationship between prostate cancer (PCa) and irisin levels, and whether irisin can be used as a biomarker in the diagnosis of PCa. MATERIALS AND
methodsFor the study groups, 50 primary PCa patients and 30 healthy male subjects were included in the PCa and healthy control groups, respectively. All volunteers in the healthy control group were screened for prostate cancer and other malignancies and chronic diseases. Volunteers who were determine to be completely healthy were included for healthy control group. In the serum samples of the subjects were measured free PSA, total PSA and irisin levels. Irisin levels were compared separately in terms of the Gleason scores and T stage. In addition to intergroup comparisons, the ROC curve for the irisin was plotted and power analysis was performed.
resultsFree and total PSA levels in the PCa group were significantly higher compared to the healthy control group (p<0.05). In addition, irisin levels in the PCa group were significantly lower than in the healthy control group (p<0.05). There was no significant difference between irisin levels in the groups classified in terms of Gleason scores (p>0.05). When the cut-off value was taken as 8.1, the sensitivity and specificity of irisin for PCa were as 80.5% and 90%, respectively.
conclusionThe results of this study indicate that the levels of irisin in the PCa group are considerably reduced and irisin may be used as a biomarker as well as free and total PSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.